Celltrion announced on the 23rd that it has donated 500 million won to the National Disaster Relief Association for those affected by the heavy rainfall. The funds will support emergency relief supplies, the installation of temporary housing, the restoration of damaged facilities, and the livelihoods of those impacted. A Celltrion official said, "I hope the affected residents can return to their daily lives."
Ildong Pharmaceutical announced on the 23rd that it has launched "Panthenol Care Ointment." This is an over-the-counter medication containing dexpanthenol. Dexpanthenol converts to vitamin B5 when absorbed into the skin, helping to protect the skin. It assists in the auxiliary treatment of dermatitis, eczema, burns, wounds, and pressure ulcers.
Dong-A Pharmaceutical announced on the 23rd that it will provide medications to the Korean Pharmaceutical Association to support areas affected by heavy rainfall, including Sancheong in Gyeongsangnam-do and Yesan in Chungcheongnam-do. The medications include cold medicine Panpirin and Champ, laxative Benachio, and energy tonic Bacchus. A Dong-A Pharmaceutical official said, "I hope this support can be of some help to the residents suffering from the damage caused by the flooding."
Dong-A ST's subsidiary Dong-A Pharmed announced on the 23rd that its sterilizing disinfectant tissue "ED WIPES HP" has received approval from the Chemical Safety Agency for efficacy against tuberculosis bacteria and multi-drug resistant bacteria. This product is a disinfectant tissue for infection control in medical institutions, and its main ingredient is hydrogen peroxide. The company explains that hydrogen peroxide decomposes into water and oxygen naturally.
CHA Biotech announced on the 23rd that it held a topping-out ceremony at the construction site of "CGB" in Pangyo Techno Valley. CGB is a facility for cell and gene therapies. Attendees included Lee Hyung-hoon, the 2nd Vice Minister of Health and Welfare; Shin Sang-jin, the Mayor of Seongnam; Cha Kwang-ryeol, the director of CHA Hospital and the global comprehensive research center of CHA Biotech; Kim Han-joong, the chairman of CHA University; and Choi Seok-yoon, the vice president of CHA Biotech.
Sanofi announced on the 23rd that it has signed a business agreement with the artificial intelligence (AI) corporation DeepCadio to improve the diagnostic environment for Fabry disease. Fabry disease is a genetic rare disease characterized by the accumulation of glycosphingolipids in cells, affecting the kidneys, heart, and nervous system, and can lead to death if severe. Sanofi will provide disease information. DeepCadio plans to develop an AI program that allows medical professionals to early detect high-risk groups for Fabry disease.
Samsung Medical Center announced on the 23rd that it will hold the "1st Symposium on Quality of Life for Cancer Patients" on the 30th. The event will address integrated strategies for the recovery of daily life for cancer patients, covering government policies, the latest treatment updates, and issues related to daily life.
A symposium titled "My Breast Cancer Story: The Journey and Hope of Young Women, Us" will be held on the 26th at the auditorium on the 6th floor of the East Building at Seoul Asan Medical Center. It will provide information about breast cancer treatment and life afterward. Medical staff and patients will be able to communicate together. The multidisciplinary collaborative decision-making process for preserving fertility in young breast cancer patients, known as MYBC, is hosted by the breast surgery department of Seoul Asan Medical Center.